Elacestrant is a selective estrogen receptor degrader (SERD) used as an anticancer medication for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer in patients… Read more


















































Elacestrant is a selective estrogen receptor degrader (SERD) used as an anticancer medication for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer in patients who have progressed following endocrine therapy. This category provides comprehensive analytical tools for drug development and quality control, including high-purity reference standards for the Elacestrant active pharmaceutical ingredient, its stereoisomers, and degradation products. Laboratories rely on these materials for accurate impurity profiling, supporting the development of robust analytical methods such as HPLC and LC-MS. The collection also features a variety of stable isotope labelled compounds, which are essential for use as internal standards in bioanalytical mass spectrometry studies, ensuring precision in quantification and metabolite identification during clinical and regulatory research.